Psychologist and/or Group Facilitator

Ramsay Health Care vs Sonic Healthcare: which healthcare stock is better value? Which offers better value - Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my pick for value. Published October 6, 3:00 pm AEDT Ramsay Health Care vs Sonic Healthcare shares. If you're weighing up Ramsay Health Care Ltd (ASX: RHC) and Sonic Healthcare Ltd (ASX: SHL) shares, you're not alone - these two are among the brightest lights in Australian healthcare. Yet, their business models, dividend policies and current market valuations are quite different. For value-seeking investors, there's a lot to unpack, so let's compare their fundamentals, dividend history, recent share price performance and what I think is the smarter buy right now. The case for Ramsay Health Care. Ramsay Health Care is one of the world's largest private hospital operators, with a vast portfolio spanning around 500 facilities - including hospitals, day surgeries, clinics, and mental health services - across 11 countries. Beyond Australia, Ramsay has substantial operations in Europe and the UK, and, according to its company profile, derives most of its revenue from Australia and Europe. This makes it a genuine global healthcare heavyweight, with a long track record in running complex, capital-intensive medical infrastructure. A couple of key numbers stand out. First, Ramsay's market cap sits at $12.58 billion, above Sonic's, marking it as the larger of the two companies. Its P/E ratio is 41.00, reflecting a rich valuation, especially compared to most of the market. Dividend hunters will note its 1.63% yield, but every cent of that payout is fully franked (100%). Its dividend per share for the most recent period was $0.97, again, all franked. The case for Sonic Healthcare. Sonic Healthcare is a global leader in pathology and diagnostic services. It's the largest private medical laboratory and pathology provider in key markets including Australia, the UK, Germany, and Switzerland. Most of Sonic's revenue comes from pathology, but the business also has a significant footprint in diagnostic imaging and medical centre operations in Australia, making it a diversified diagnostics powerhouse. Fundamentally, Sonic's story right now is quite different to Ramsay's. Its market capitalisation is $9.20 billion, a fair bit smaller than Ramsay's. But here's where things get interesting for value investors: its P/E ratio is 15.44, easily less than half of Ramsay's, suggesting Sonic shares are much more modestly valued at current earnings levels. Its dividend yield is a chunky 5.69%, and while only 60% franked for the latest payout, that's still a potentially appealing income stream. Recent dividends have totalled $1.08 per share. Valuation comparison. With several key differences apparent, here's how Ramsay and Sonic line up on the numbers that matter for value-focused investors: Note: Ramsay's reported P/E ratio may be based on a different earnings measure (e.g. underlying or forward earnings) than the EPS figure shown, which is why they may appear inconsistent. Simply put, if I'm judging pure valuation metrics, Sonic Healthcare looks much more attractively priced relative to its earnings and offers a much higher dividend yield, albeit with less franking than Ramsay. Ramsay's high P/E suggests the market is baking in a lot of future growth or sees it as much lower risk - or possibly a bit of both. Recent share price momentum. Comparing recent share price performance up to1 October 2026: * Ramsay Health Care closed at $54.48 on 1 Oct 2026, down 2.16% on the day but boasting impressive momentum over 2026 with a year-to-date return of 64.7%. * Sonic Healthcare finished at $18.61 on 1 Oct 2026, also dropping 2.00% that day, and is down 11.2% for the year to date. Over the past year, Ramsay has surged ahead and Sonic has gone backwards. For investors looking for momentum and the market's latest vote of confidence, Ramsay clearly wears the crown for 2026 so far. Which is the better buy? For me, as a value-seeking investor, Sonic Healthcare is the better buy right now. Here's why: Sonic's P/E ratio of 15.44 is far lower than Ramsay's 41.00, and yet its earnings per share are pretty similar. Even better, Sonic's dividend yield is well over three times Ramsay's (5.69% vs 1.63%), though franking is only 60% versus Ramsay's full 100%. Ramsay has had a great run this year, reflected in its huge year-to-date return, but that's precisely why I'd be cautious about buying it now - it's probably priced for perfection. Sonic, meanwhile, has lagged in the share price stakes and may well be out of favour, but it's this relative unloved status that gives it value appeal. Its business is less capital intensive, cash-generative and, in my eyes, looks like a classic opportunity for patient investors to scoop up a top ASX healthcare stock at a fair valuation, with a strong, fully-funded dividend yield to boot. So, if I had to buy one for value today, my pick would be Sonic Healthcare.

$26.5m surgical centre for Campbelltown. A new private surgical centre with operating theatres, inpatient beds and around 35 new jobs is planned for Campbelltown as Ramsay Health Care expands its footprint in South West Sydney. The $26.5 million Ramsay Surgical Centre Campbelltown is expected to open in mid-2028 within the Macarthur Health Precinct, giving patients greater access to specialist surgery closer to home. The purpose-built centre will feature three operating theatres, including a dedicated procedure room, with capacity for a fourth theatre as demand grows. It will also include 12 inpatient beds and provide surgery across orthopaedics, general surgery, endoscopy, gynaecology, ear, nose and throat, urology and plastic surgery. Around 35 jobs are expected to be created initially, including positions for nurses, allied health professionals and other healthcare workers. Ramsay's National Growth & Partnerships Manager Claire Thurwood said the investment responded to Campbelltown's rapidly growing population. "As our community grows, we want more patients to be able to access the surgical care they need locally, without having to travel further across Sydney," Thurwood said. NSW Government projections estimate Campbelltown's population will increase by more than 45,000 people between 2021 and 2041, placing increasing demand on local health services. The centre will form part of the Macarthur Health Precinct, developed by Vital Health Care Property Trust, where Stage 1 has already opened with the GenesisCare Integrated Cancer & Health Centre. "The centre has been designed to support a broad range of surgical care, with modern operating theatres and inpatient facilities giving our specialists greater flexibility in how they care for their patients," Thurwood said. She said the centre would complement existing health services while increasing choice for patients across the region. "This is a significant investment in the future of healthcare in Campbelltown and will give patients more options to access specialist surgical care locally," she said. "We're looking forward to welcoming our first patients in 2028 and providing another option for high-quality surgical care in South West Sydney."